Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,163.8
-20.8 (-0.65%)

 

  • STI Straits Times Index
    3,163.8
    -20.8 (-0.65%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,606.5
    -5.7 (-0.36%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    28,437.7
    -261.1 (-0.91%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,420.6
    -30.1 (-0.87%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    29,587.5
    -180.5 (-0.61%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    5,989.1
    -81.2 (-1.34%)
    Index delayed 10 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 1,023.8M
  • Value: 729.2M
  • Rise: 70
  • Fall: 247
  • Unch: 455

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Sembcorp Marine0.195-0.005
Jiutian Chemical0.096+0.004
Thomson Medical0.114+0.002
Golden Agri-Res0.215-
Anchor Resources0.025+0.001
Singtel2.420-0.010
Oceanus^0.042-0.001
QT Vascular0.006-0.001
ThaiBev0.760-0.010
Mercurius0.064-0.006

World Indices

World Indices
Name Last Change
Nasdaq 13,900.2 +70.9
HSI 28,392.4 -306.4
HSCEI 10,850.8 -126.6
Jakarta 5,989.1 -81.2
Nikkei 225 29,552.8 -215.2
SSE Comp 3,418.1 -32.6
Shanghai A 3,582.7 -34.2
Shanghai B 245.5 -2.0
KOSPI 3,132.6 +0.7

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

Lonza LONZA GROUP LTD
Quotes 10 Minutes Delayed. Updated at 12 Apr 2021 07:12
Last (SGD): 79.970 Change: - High: - Remarks: CD
Remarks legend:
RemarksDescriptionRemarksDescription
SuspSuspendedIMMImmediate Delivery
PLPending ListingPAPending Announcement
DLDelistedCTConditional Trading
CWConditional When IssueWIWhen Issue
BIBuyIn OnlyJAdjust
HTrading HaltCDCum Dividend
XDEx DividendCBCum Bonus
XBEx BonusCRCum Rights
XREx RightsCOCum Offer
XOEx OfferCECum Entitlement
XEEx EntitlementCICum Interest
XIEx InterestCACum All
XAEx AllSCScripless Conversion
CIRBCircuit Breaker TriggeredCIRHHalt due to Circuit Breaker Triggered
Change (%): - Low: -
Open - Yesterday's Close 79.970
Buy Price - Sell Price -
Buy Volume ('000) - Sell Volume ('000) -
Cumulative Volume ('000) - Cumulative Value -
Click to show Stock Prices chart

Key Statistics

EPS (SGD) a 17.53581 Trailing EPS (SGD) e 17.53581 NAV (SGD) b 136.8358
PE a 4.560 Trailing PE f 4.560 Price / NAV b 0.5844
Dividend (SGD) d 4.497300 Cash In Hand (SGD) g 9.9887 Issued & Paid-up Shares c 74,289,000
Dividend Yield (%) d 5.624 Price / Cash In Hand g 8.006 Treasury Shares h 180,000
Beta - 75 Daysi - R-Squared - 75 Days(%)i - Market Cap (M) 5,940.891
Beta - 500 Daysi - R-Squared - 500 Days (%)i - Enterprise Value (M) 10,669.053
Piotroski F Score 6 Exchange Code O6Z Par Value ( CHF ) 1.00000
52 Weeks Volatility (%) 0.0 6-Month VWAP n.a. Free Float (%) 99.9
Under CPF Investment Scheme (CPFIS) No
Sector & Industry Manufacturing - Biotechnology
Category Classification Foreign Listing (Others) / Medical & Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 27 Jul 2020.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 27 Jul 2020.
  9. Beta and R-Squared are calculated in relation to the market index (STI or KLCI) using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference Lonza SGX 5,940.891 4.560 4.560 0.5844 5.624
Industry Biotechnology SGX 2,992.412 4.594 4.594 0.5877 5.582
Foreign Listing (Others) SGX 7,484.339 22.705 15.955 1.7707 1.780
Medical & Biotechnology SGX 966.903 19.747 18.928 1.3789 2.044
Local Peer Suntar Eco-City SGX 43.932 500.000 499.226 2.4180 -
Global Peer AMGEN INC NASDAQ 143,345.908 19.734 19.734 15.2350 2.582
Global Peer CSL LTD ASX 119,878.608 38.223 31.499 11.3443 1.114
Global Peer GILEAD SCIENCES INC NASDAQ 81,817.226 665.202 665.181 4.4950 4.169
Global Peer ILLUMINA INC NASDAQ 58,851.683 89.713 89.713 12.5376 -
Global Peer MODERNA INC NASDAQ 56,393.366 - - 22.0167 -
Global Peer VERTEX PHARMACEUTICAL NASDAQ 55,462.466 20.453 20.453 6.3847 -
Global Peer WUXI BIO HKEx 426,357.257 224.657 224.660 17.4866 -
Global Peer REGENERON PHARMACEUTICALS INC NASDAQ 50,905.898 14.490 14.490 4.6172 -
Global Peer BIOGEN INC NASDAQ 40,851.945 10.211 10.211 3.8178 -
Global Peer ALEXION PHARMACEUTICAL INC NASDAQ 34,078.638 56.478 56.478 2.9249 -
Other Global Peers BIONTECH SE SPON ADS EACH REP 1 ORD SHS (NASDAQ), BEIGENE (HKEx), BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS (NASDAQ), SEAGEN INC (NASDAQ), EXACT SCIENCES CORP (NASDAQ), 10X GENOMICS INC (NASDAQ), SINO BIOPHARM (HKEx), INCYTE CORPORATION (NASDAQ), ALNYLAM PHARMACEUTICALS INC (NASDAQ), BIO-TECHNE CORP (NASDAQ), BIOMARIN PHARMACEUTICAL (NASDAQ), NOVAVAX INC (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), ZAI LAB-SB (HKEx), NEUROCRINE BIOSCIENCES INC (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), MIRATI THERAPEUTICS INC (NASDAQ), BRIDGEBIO PHARMA INC (NASDAQ), ACCELERON PHARMA (NASDAQ), ABCELLERA BIOLOGICS INC (NASDAQ), FATE THERAPEUTICS (NASDAQ), EXELIXIS INC (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), TG THERAPEUTICS INC (NASDAQ), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), IONIS PHARMACEUTICALS INC (NASDAQ), SANA BIOTECHNOLOGY INC (NASDAQ), SAREPTA THERAPEUTICS INC (NASDAQ), KODIAK SCIENCES INC (NASDAQ), VIR BIOTECHNOLOGY INC (NASDAQ), BLUEPRINT MEDICINES CORP (NASDAQ), GALAPAGOS NV SPON ADR REPR 1 ORD SHS (NASDAQ), JOINN (HKEx), INTELLIA THERAPEUTICS INC (NASDAQ), ALLOGENE THERAPEUTICS INC (NASDAQ), CHINA BIOLOGIC PRODUCTS HLDGS INC (NASDAQ), ABCAM PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), OLINK HLDG AB SPON ADS EACH REP 1 ORD SHS (NASDAQ), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), BEAM THERAPEUTICS INC (NASDAQ), EMERGENT BIOSOLUTIONS INC (NYSE), ARENA PHARMACEUTICALS INC (NASDAQ), GENSCRIPT BIO (HKEx), AGIOS PHARMACEUTICALS INC (NASDAQ), VERACYTE INC (NASDAQ), CHEMOCENTRYX INC (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), INSMED INC (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), SEER INC (NASDAQ), NANOSTRING TECHNOLOGIES INC (NASDAQ), ARVINAS INC (NASDAQ), RELAY THERAPEUTICS INC (NASDAQ), ALKERMES PLC (NASDAQ), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), ORGANOGENESIS HOLDINGS INC (NASDAQ), INSTIL BIO INC (NASDAQ), EDITAS MEDICINE INC (NASDAQ), INTRA-CELLUAR THERAPIES INC (NASDAQ), LIGAND PHARMACEUTICAL INC (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), DECIPHERA PHARMACEUTICALS INC (NASDAQ), ROCKET PHARMACEUTICALS INC (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), 3SBIO (HKEx), XENCOR INC (NASDAQ), ARCUS BIOSCIENCES INC (NYSE), NUVATION BIO INC (NYSE), MYRIAD GENETICS INC (NASDAQ), MORPHIC HOLDING INC (NASDAQ), SORRENTO THERAPEUTICS INC (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), BIONANO GENOMICS INC (NASDAQ), NGM BIOPHARMACEUTICALS INC (NASDAQ), KURA ONCOLOGY INC (NASDAQ), BLUEBIRD BIO INC (NASDAQ), SERES THERAPEUTICS (NASDAQ), MACROGENICS INC (NASDAQ), APPLIED MOLECULAR TRANSPORT INC (NASDAQ), BIOCRYST PHARMACEUTICALS INC (NASDAQ), PANDION THERAPEUTICS INC (NASDAQ), FIVE PRIME THERAPEUTICS (NASDAQ), VIVA BIOTECH (HKEx), JW THERAP-B (HKEx), CYTOKINETICS INC (NASDAQ), PURETECH HEALTH PLC SPON ADS EACH REP 10 ORD SHS (NASDAQ), FIBROGEN INC (NASDAQ), MYOVANT SCIENCES LTD (NYSE), PRELUDE THERAPEUTICS INC (NASDAQ), AURINIA PHARMACEUTICALS INC (NASDAQ), BIOATLA INC (NASDAQ), JACOBIO-B (HKEx), SANGAMO THERAPEUTICS INC (NASDAQ), KINTOR PHARMA-B (HKEx), LUMINEX CORP(DEL) (NASDAQ), TRAVERE THERAPEUTICS INC (NASDAQ), IMMUNOVANT INC (NASDAQ), ZENTALIS PHARMACEUTICALS INC (NASDAQ), UNIQURE N.V. (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), ALLOVIR INC (NASDAQ), IMMUNOGEN INC (NASDAQ), KYMERA THERAPEUTICS INC (NASDAQ), REGENXBIO INC (NASDAQ), IMMUNOCORE HLDGS PLC SPON ADS EACH REP ONE ORD SHS (NASDAQ), POLYNOVO LIMITED (ASX), CARA THERAPEUTICS INC (NASDAQ), EDGEWISE THERAPEUTICS INC (NASDAQ), PRECIGEN INC (NASDAQ), MIMEDX GROUP INC (NASDAQ), HAOHAI BIOTEC (HKEx), C4 THERAPEUTICS INC (NASDAQ), REPLIMUNE GROUP INC (NASDAQ), ALECTOR INC (NASDAQ), ALPHAMAB-B (HKEx), FRONTAGE (HKEx), COMPASS PATHWAYS PLC UNSPON ADS REP 1 ORD SHS (NASDAQ), OCUGEN INC (NASDAQ), TRANSLATE BIO INC (NASDAQ), STOKE THERAPEUTICS INC (NASDAQ), PLIANT THERAPEUTICS INC (NASDAQ), VOR BIOPHARMA INC (NASDAQ), AVID BIOSERVICES INC (NASDAQ), SHATTUCK LABS INC (NASDAQ), PROTAGONIST THERAPEUTICS INC (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), AFFIMED N V (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), OMEROS CORP (NASDAQ), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), MESOBLAST LTD (ASX), MERSANA THERAPEUTICS INC (NASDAQ), MERIDIAN BIOSCIENCE INC COM (NASDAQ), TRILLIUM THERAPEUTICS INC (NASDAQ), SYNDAX PHARMACEUTICALS INC (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), NKARTA INC (NASDAQ), CURIS INC (NASDAQ), ASCENTAGE-B (HKEx), MANNKIND CORPORATION (NASDAQ), VAXCYTE INC (NASDAQ), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), COHERUS BIOSCIENCES INC (NASDAQ), HUMANIGEN INC (NASDAQ), PERSONALIS INC (NASDAQ), 4D MOLECULAR THERAPEUTICS INC (NASDAQ), PROTHENA CORP PLC (NASDAQ), JHBP-B (HKEx), CORTEXYME INC (NASDAQ), ENANTA PHARMACEUTICALS INC (NASDAQ), ITEOS THERAPEUTICS INC (NASDAQ), RADIUS HEALTH INC (NASDAQ), TELIX PHARMACEUTIC (ASX), VANDA PHARMACE INC (NASDAQ), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), BLACK DIAMOND THERAPEUTICS INC (NASDAQ), GRACELL BIOTECHNOLOGIES INC SPON ADS EACH REP 5 ORD SHS (NASDAQ), BIOXCEL THERAPEUTICS INC (NASDAQ), PASSAGE BIO INC (NASDAQ), MERUS B V (NASDAQ), DYNE THERAPEUTICS INC (NASDAQ), EPIZYME INC (NASDAQ), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), AVIDITY BIOSCIENCES INC (NASDAQ), TAYSHA GENE THERAPIES INC (NASDAQ), ADAPTIMMUNE THERAPEUTICS PLC SPON ADS EACH REP 6 ORD SHS (NASDAQ), LEXICON PHARMACEUTICALS INC (NASDAQ), INHIBRX INC (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), KARYOPHARM THERAPEUTICS INC (NASDAQ), IMMATICS N V (NASDAQ), HARPOON THERAPEUTICS INC (NASDAQ), ARDELYX INC (NASDAQ), CHIMERIX INC (NASDAQ), VBI VACCINES INC CDA (NASDAQ), ZIOPHARM ONCOLOGY INC (NASDAQ), ATHIRA PHARMA INC (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), COMPUGEN (NASDAQ), ASPIRA WOMENS HEALTH INC (NASDAQ), GREENWICH LIFESCIENCES INC (NASDAQ), BICYCLE THERAPEUTICS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), IMUGENE LIMITED (ASX), VAXART INC (NASDAQ), CLOVIS ONCOLOGY INC (NASDAQ), ACTINIUM PHARMACEUTICALS INC (NYSE American), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), KADMON HLDGS INC (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), MEIRAGTX HOLDINGS PLC (NASDAQ), SOLID BIOSCIENCES INC (NASDAQ), ANAPTYSBIO INC (NASDAQ), AGENUS INC (NASDAQ), ALDEYRA THERAPEUTICS (NASDAQ), SIGILON THERAPEUTICS INC (NASDAQ), RIGEL PHARMACEUTICALS INC (NASDAQ), INVENTIVA SA SPON ADS EACH REP 1 ORD SHS (NASDAQ), POSEIDA THERAPETUICS INC (NASDAQ), FORTE BIOSCIENCES INC (NASDAQ), IVERIC BIO INC (NASDAQ), RAPT THERAPEUTICS INC (NASDAQ), FORTRESS BIOTECH INC (NASDAQ), NEOLEUKIN THERAPEUTICS INC (NASDAQ), SINOMAB BIO-B (HKEx), IKENA ONCOLOGY INC (NASDAQ), CYTOMX THERAPEUTICS INC (NASDAQ), XBIOTECH INC (NASDAQ), DPHARMA (Bursa), JOUNCE THERAPEUTICS INC (NASDAQ), CHEMOMAB THERAPEUTICS LTD SPON ADS EACH REP 20 ORD SHS (NASDAQ), PRECISION BIOSCIENCES INC (NASDAQ), ALTIMMUNE INC (NASDAQ), AKOUOS INC (NASDAQ), TERNS PHARMACEUTICALS INC (NASDAQ), FREELINE THERAPEUTICS HLDGS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), VERASTEM INC (NASDAQ), SPECTRUM PHARMACEUTICALS INC (NASDAQ), GERON CORP (NASDAQ), AVROBIO INC (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), AKEBIA THERAPEUTICS INC (NASDAQ), SUMMIT THERAPEUTICS INC (NASDAQ), LEE'S PHARM (HKEx), APTOSE BIOSCIENCES INC (NASDAQ), MOLECULAR TEMPLATES INC (NASDAQ), SINOVAC BIOTECH LTD (NASDAQ), ATRECA INC (NASDAQ), FOGHORN THERAPEUTICS INC (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), XOMA CORP (NASDAQ), VIKING THERAPEUTICS INC (NASDAQ), SENSEI BIOTHERAPEUTICS INC (NASDAQ), UROGEN PHARMA LTD (NASDAQ), SESEN BIO INC (NASDAQ), SEELOS THERAPEUTICS INC (NASDAQ), OPTHEA LIMITED SPON ADS EACH REPR 8 ORD SHS (NASDAQ), HOMOLOGY MEDICINES INC (NASDAQ), OPTHEA LIMITED (ASX), LINEAGE CELL THERAPEUTICS INC (NYSE American), ADICET BIO INC (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), ASCLETIS-B (HKEx), SYROS PHARMACEUTICALS INC (NASDAQ), ESSEX BIO-TECH (HKEx), PROQR THERAPEUTICS N V (NASDAQ), LANDOS BIOPHARMA INC (NASDAQ), LAVA THERAPEUTICS NV (NASDAQ), ATHERSYS INC (NASDAQ), SQZ BIOTECHNOLOGIES CO (NYSE), OUTLOOK THERAPEUTICS INC (NASDAQ), PUMA BIOTECHNOLOGY INC (NASDAQ), CUE BIOPHARMA INC (NASDAQ), PARATEK PHARMACEUTICALS INC (NASDAQ), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), 22ND CENTURY GROUP INC (NYSE American), FREQUENCY THERAPEUTICS INC (NASDAQ), AEGLEA BIOTHERAPEUTICS INC (NASDAQ), SPRUCE BIOSCIENCES INC (NASDAQ), ONCORUS INC (NASDAQ), ANTEOTECH LIMITED (ASX), PORTAGE BIOTECH INC (NASDAQ), BELLUS HEALTH INC (NASDAQ), INNATE PHARMA SPON ADS EACH REP 1 ORD SHS (NASDAQ), SURFACE ONCOLOGY INC (NASDAQ), IMMUNOME INC (NASDAQ), UNITY BIOTECHNOLOGY INC (NASDAQ), ARBUTUS BIOPHARMA CORP (NASDAQ), VIRACTA THERAPEUTICS INC (NASDAQ), VISTAGEN THERAPEUTICS INC (NASDAQ), COGENT BIOSCIENCES INC (NASDAQ), WAVE LIFE SCIENCES LTD (NASDAQ), CYMABAY THERAPEUTICS INC (NASDAQ), NANOVIRICIDES INC (NYSE American), INFINITY PHARMACEUTICALS INC (NASDAQ), KEZAR LIFE SCIENCES INC (NASDAQ), TREVENA INC (NASDAQ), 9 METERS BIOPHARMA INC (NASDAQ), EIGER BIOPHARMACEUTICALS INC (NASDAQ), CASI PHARMACEUTICALS INC (NASDAQ), KAMADA LTD (NASDAQ), ALPINE IMMUNE SCIENCES INC (NASDAQ), EDAP TMS S.A. SPON ADR EACH REPR 1 ORD SHARE (NASDAQ), NEXTCURE INC (NASDAQ), CO DIAGNOSTICS INC (NASDAQ), HARVARD BIOSCIENCE INC (NASDAQ), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), CABALETTA BIO INC (NASDAQ), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), DECIBEL THERAPEUTICS INC (NASDAQ), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), IMMUNOPRECISE ANTIBODIES LTD (NASDAQ), ITERUM THERAPEUTICS PLC (NASDAQ), IMMUTEP LTD (ASX), AVEO PHARMACEUTICALS INC (NASDAQ), MEDICINOVA INC (NASDAQ), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), BIOVIE INC (NASDAQ), CHECKMATE PHARMACEUTICALS INC (NASDAQ), T2 BIOSYSTEMS INC (NASDAQ), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), LARIMAR THERAPEUTICS INC (NASDAQ), SAVARA INC (NASDAQ), ADMA BIOLOGICS INC (NASDAQ), MEDICENNA THERAPEUTICS CORP (NASDAQ), ONCOLYTICS BIOTECH INC (NASDAQ), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), SIERRA ONCOLOGY INC (NASDAQ), NEXT SCIENCE LTD (ASX), EQUILLIUM INC (NASDAQ), IMV INC (NASDAQ), ONCONOVA THERAPEUTICS INC (NASDAQ), HEAT BIOLOGICS INC (NASDAQ), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), EVOGENE LTD (NASDAQ), DIAMEDICA THERAPEUTICS INC (NASDAQ), EVOFEM BIOSCIENCES INC (NASDAQ), VOYAGER THERAPEUTICS INC (NASDAQ), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), INMUNE BIO INC (NASDAQ), KAZIA THERAPEUTICS LIMITED (ASX), CHIASMA INC (NASDAQ), IMMUTEP LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), CALITHERA BIOSCIENCES INC (NASDAQ), ENZO BIOCHEM INC (NYSE), PIERIS PHARMACEUTICALS INC (NASDAQ), CONTRAFECT CORP (NASDAQ), AXCELLA HEALTH INC (NASDAQ), FENNEC PHARMACEUTICALS INC (NASDAQ), CATALYST BIOSCIENCES INC (NASDAQ), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), GAIN THERAPEUTICS INC (NASDAQ), BIOMX INC (NYSE American), SIO GENE THERAPIES INC (NASDAQ), X4 PHARMACEUTICALS INC (NASDAQ), CHAMPIONS ONCOLOGY INC (NASDAQ), CEL-SCI CORP (NYSE American), GALECTIN THERAPEUTICS INC (NASDAQ), PLURISTEM THERAPEUTICS INC (NASDAQ), GLYCOMIMETICS INC (NASDAQ), CONCERT PHARMACEUTICALS INC (NASDAQ), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), ENOCHIAN BIOSCIENCES INC (NASDAQ), BIONOMICS LTD (ASX), DYADIC INTERNATIONAL INC (NASDAQ), GENOCEA BIOSCIENCES INC (NASDAQ), ANIXA BIOSCIENCES INC (NASDAQ), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), IBIO INC (NYSE American), AZIYO BIOLOGICS INC (NASDAQ), METACRINE INC (NASDAQ), TRACON PHARMACEUTICALS INC (NASDAQ), AETERNA ZENTARIS INC (NASDAQ), SYNLOGIC INC (NASDAQ), BRAINSTROM CELL THERAPEUTICS (NASDAQ), ORGENESIS INC (NASDAQ), LONGEVERON INC (NASDAQ), NEUREN PHARMACEUTICALS LTD (ASX), LIMINAL BIOSCIENCES INC (NASDAQ), ELOXX PHARMACEUTICALS INC (NASDAQ), EVAXION BIOTECH AS SPON ADS EACH REP 1 ORD SHS (NASDAQ), ARMATA PHARMACEUTICALS INC (NYSE American), APTEVO THERAPEUTICS INC (NASDAQ), MINERVA NEUROSCIENCES INC (NASDAQ), VIRIDIAN THERAPEUTICS INC (NASDAQ), LA JOLLA PHARMACEUTICAL CO (NASDAQ), CIDARA THERAPEUTICS INC (NASDAQ), ARAVIVE INC (NASDAQ), OTONOMY INC (NASDAQ), AIM IMMUNOTECH INC (NYSE American), LEAP THERAPEUTICS INC (NASDAQ), ENDRA LIFE SCIENCES INC (NASDAQ), RECRO PHARMA INC (NASDAQ), PALATIN TECHNOLOGIES INC (NYSE American), CELYAD ONCOLOGY SPON ADS EACH REPR 1 ORD SHS (NASDAQ), CAPRICOR THERAPEUTICS INC (NASDAQ), INFLARX N V (NASDAQ), VASCULAR BIOGENICS LTD (NASDAQ), LUMOS PHARMA INC (NASDAQ), MATINAS BIOPHARMA HOLDINGS INC (NYSE American), AVALON GLOBOCARE CORP (NASDAQ), AIKIDO PHARMA INC (NASDAQ), LEAF RESOURCES LTD (ASX), CLEVELAND BIOLABS INC (NASDAQ), NEUROBO PHARMACEUTICALS INC (NASDAQ), DIFFUSION PHARMACEUTICALS INC (NASDAQ), COHBAR INC (NASDAQ), SYNTHETIC BIOLOGICS INC (NYSE American), MERRIMACK PHARMACEUTICALS INC (NASDAQ), UNI-BIO GROUP (HKEx), ADVAXIS INC (NASDAQ), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), VACCINEX INC (NASDAQ), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), CELLECTAR BIOSCIENCES INC (NASDAQ), CHIMERIC THERAPEUTICS LTD (ASX), PULMATRIX INCORPORATED (NASDAQ), ATYR PHARMA INC (NASDAQ), BIOCARDIA INC (NASDAQ), MONOPAR THERAPEUTICS INC (NASDAQ), ACHIEVE LIFE SCIENCE INC (NASDAQ), AZURRX BIOPHARMA INC (NASDAQ), GENETIC TECHNOLOGIES SPON ADS EA REP 600 ORD SHS(R/S) (NASDAQ), KIROMIC BIOPHARMA INC (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), CYNATA THERAPEUTICS LTD (ASX), GENETIC TECHNOLOGIES (ASX), CATABASIS PHARMACEUTICALS INC (NASDAQ), WINDTREE THERAPEUTICS INC (NASDAQ), REGENT PACIFIC (HKEx), SOLIGENIX INC (NASDAQ), CYCLACEL PHARMACEUTICALS INC (NASDAQ), NABRIVA THERAPEUTICS PLC (NASDAQ), MICROBOT MEDICAL INC (NASDAQ), IDERA PHARMACEUTICALS INC (NASDAQ), ACTINOGEN MEDICAL LTD (ASX), AURIS MEDICAL HOLDING LTD (NASDAQ), ALIMERA SCIENCES INC (NASDAQ), APPLIED DNA SCIENCES INC (NASDAQ), ARCA BIOPHARMA INC (NASDAQ), INDIA GLOBALIZATION CAPITAL INC (NYSE American), PRESCIENT THERAPEUTICS LIMITED (ASX), ALTERITY THERAPEUTICS LIMITED (ASX), FORWARD PHARMA AS SPON ADS EACH REP 14 ORD SHS (NASDAQ), ANPAC BIO MEDICAL SCIENCE CO LTD SPON ADS EACH REPR 1 ORD SHS CLASS A (NASDAQ), CT ENTERPRISE (HKEx), BIO-PATH HOLDINGS INC (NASDAQ), OPIANT PHARMACEUTICALS INC (NASDAQ), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), CYCLO THERAPEUTICS INC (NASDAQ), INVEX THERAPEUTICS LTD NPV (ASX), LIXTE BIOTECHNOLOGY HOLDINGS INC (NASDAQ), ADITX THERAPEUTICS INC (NASDAQ), ORAGENICS INC (NYSE American), HISTOGEN INC (NASDAQ), CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL (NYSE American), MEMPHASYS LTD (ASX), PATRYS LIMITED (ASX), ACORDA THERAPEUTICS INC (NASDAQ), SONNET BIOTHERAPEUTICS HLDGS INC (NASDAQ), PRECIPIO INC (NASDAQ), PHIO PHARMACEUTICALS CORP (NASDAQ), BIOTRON (ASX), AUSTRALIAN PRIMARY HEMP LTD (ASX), AVECHO BIOTECHNOLOGY LTD (ASX), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ), CONTANGO ASSET MANAGEMENT LIMITED (ASX), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), ADALTA LTD (ASX), BRIACELL THERAPEUTICS CORP (NASDAQ), BELLICUM PHARMACEUTICALS (NASDAQ), GEOVAX LABS INC (NASDAQ), REGENEUS LTD (ASX), INMED PHARMACEUTICALS INC (NASDAQ), MIDATECH PHARMA PLC SPON ADS EACH REP 5 ORD SHS(R/S) (NASDAQ), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), BIOSINO BIO-TEC (HKEx), SENECA BIOPHARMA INC (NASDAQ), RHINOMED LIMITED (ASX), BENITEC BIOPHARMA INC (NASDAQ), AMPLIA THERAPEUTICS LTD (ASX), CONSTELLATION TECHNOLOGIES LTD (ASX), SENESTECH INC (NASDAQ), XENETIC BIOSCIENCES INC (NASDAQ), XTL BIOPHARMACEUTICALS LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), NOVABAY PHARMACEUTICALS INC (NYSE American), HOLISTA COLLTECH LIMITED (ASX), CELLECT BIOTECHNOLOGY LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), ANATARA LIFESCIENCES LTD (ASX), NANOLLOSE LTD (ASX), CRYOSITE (ASX), HAO WEN HLDGS (HKEx), LIVING CELL TECHNOLOGIES (ASX), FACTOR THERAPEUTICS LIMITED (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

Not enough data to show total shareholder returns
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 79.970 - 79.970 Change From 1 Year Low - % Change From 1 Year Low (%) -
Change From 1 Year High - % Change From 1 Year High (%) -
2 Years Range 79.970 - 79.970 Change From 2 Years Low - % Change From 2 Years Low (%) -
Change From 2 Years High - % Change From 2 Years High (%) -
5 Years Range 79.970 - 79.970 Change From 5 Years Low - % Change From 5 Years Low (%) -
Change From 5 Years High - % Change From 5 Years High (%) -
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Lonza Group Ltd is a corporation incorporated under the laws of Switzerland and has been listed on the SIX Swiss Exchange (the “SIX”) since November 1999.Lonza is a supplier to the pharmaceutical, healthcare and life sciences industries with products and services spanning from research to final product manufacture to meet customers' needs. The products Lonza manufacture for the life sciences industry can be characterised as very complex molecules which are manufactured in a highly regulated environment and will end up in the body of human beings or animals.Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. The Group has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. The Group provides cell-based research, endotoxin detection and cell therapy manufacturing. The Group is also a provider of high value chemicals and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.To provide optimal support to its customers, the Group is organized into three business divisions, namely, Custom Manufacturing, Life Science Ingredients and Bioscience, which focus on specific sets of customers and their needs.

IPO Performance

Listing Date 21 Oct 2011 Full Subscription Rate (x) -
No of Placement Shares (M) - No of Public Offer Shares (M) - Public Offer Subscription Rate (x) -
IPO Price (SGD) a - First Day Close (SGD) a 79.970 First Week Close (SGD) a 79.970
Current vs IPO Price (%) - First Day Gain (%) - First Week Gain (%) -
Notes:
  1. Adjusted for the following: IPO Price is not available as there are no issue of Shares under the Listing by way of Introduction.

Reports Download

Report Type Financial Year Ended Download
Annual Report
Annual Report 2020 Dec 2020 Part 1(0.46 MB)
Part 2(13.07 MB)
Annual Report 2019 Dec 2019 Part 1(0.15 MB)
Part 2(18.45 MB)
Annual Report 2018 Dec 2018 Part 1(7.67 MB)
Annual Report 2017 Dec 2017 Part 1(10.98 MB)
Annual Report 2016 Dec 2016 Part 1(7.93 MB)
Annual Report 2015 Dec 2015 Part 1(1.90 MB)
Part 2(2.28 MB)
Annual Report 2014 Dec 2014 Part 1(3.90 MB)
Part 2(6.06 MB)
Annual Report 2013 Dec 2013 Part 1(3.42 MB)
Annual Report 2012 Dec 2012 Part 1(3.87 MB)
Annual Report 2011 Dec 2011 Part 1(5.01 MB)

Historical Price Data

Date Open High Low Close Volume VWAP
09 Apr 2021 79.970 79.970 79.970 79.970 - -
08 Apr 2021 79.970 79.970 79.970 79.970 - -
07 Apr 2021 79.970 79.970 79.970 79.970 - -
06 Apr 2021 79.970 79.970 79.970 79.970 - -
05 Apr 2021 79.970 79.970 79.970 79.970 - -
01 Apr 2021 79.970 79.970 79.970 79.970 - -
31 Mar 2021 79.970 79.970 79.970 79.970 - -
30 Mar 2021 79.970 79.970 79.970 79.970 - -
29 Mar 2021 79.970 79.970 79.970 79.970 - -
26 Mar 2021 79.970 79.970 79.970 79.970 - -
25 Mar 2021 79.970 79.970 79.970 79.970 - -
24 Mar 2021 79.970 79.970 79.970 79.970 - -
23 Mar 2021 79.970 79.970 79.970 79.970 - -
22 Mar 2021 79.970 79.970 79.970 79.970 - -
19 Mar 2021 79.970 79.970 79.970 79.970 - -
18 Mar 2021 79.970 79.970 79.970 79.970 - -
17 Mar 2021 79.970 79.970 79.970 79.970 - -
16 Mar 2021 79.970 79.970 79.970 79.970 - -
15 Mar 2021 79.970 79.970 79.970 79.970 - -
12 Mar 2021 79.970 79.970 79.970 79.970 - -
11 Mar 2021 79.970 79.970 79.970 79.970 - -
10 Mar 2021 79.970 79.970 79.970 79.970 - -
Summary
Current 2 Weeks
(26 Mar 2021 to 09 Apr 2021)
79.970 79.970 79.970 79.970 - -
Previous 2 Weeks
(12 Mar 2021 to 25 Mar 2021)
79.970 79.970 79.970 79.970 - -
4 Weeks from
(11 Feb 2021 to 11 Mar 2021)
79.970 79.970 79.970 79.970 - -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.
We use Cookies. By continuing to use this webite, you will be agreeing to our Privacy Policy, Terms and Conditions and Cookie Policy.